{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:34:24Z","timestamp":1795008864457,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128503","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:01:39Z","timestamp":1775030499000},"page":"128503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ability of the MenB-fHbp vaccine to provide immune protection against meningococcal serogroup B ST-1161 UK university \u201cSouth West Outbreak\u201d strain isolates"],"prefix":"10.1016","volume":"80","author":[{"given":"Jay","family":"Lucidarme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlesh Krishna","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqaiya","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez N.","family":"Ladhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128503_bb0005","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268823000328","article-title":"Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review","volume":"151","author":"Pardo de Santayana","year":"2023","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2026.128503_bb0010","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128503_bb0015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1186\/s12889-022-13342-2","article-title":"Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review","volume":"22","author":"Shen","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2026.128503_bb0020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14760584.2024.2329618","article-title":"The important lessons lurking in the history of meningococcal epidemiology","volume":"23","author":"Borrow","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128503_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/vaccines6010012","article-title":"Meningococcal vaccines: current status and emerging strategies","volume":"6","author":"McCarthy","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128503_bb0030","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1056\/NEJMoa2214924","article-title":"Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia","volume":"388","author":"Haidara","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128503_bb0035","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0140-6736(24)00880-8","article-title":"Nigeria rolls out novel meningitis vaccine","volume":"403","author":"Ashinze","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128503_bb0040","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/14760584.2022.2064850","article-title":"Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage","volume":"21","author":"Findlow","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128503_bb0045","unstructured":"UK Health and Security Agency Guidance for Public Health Management of Meningococcal Disease in the UK. https:\/\/assets.publishing.service.gov.uk\/media\/673257250a2b4132b43d1448\/UKHSA-meningo-disease-guidelines-november2024.pdf; 2024. [Accessed 13 June 2025]."},{"key":"10.1016\/j.vaccine.2026.128503_bb0050","series-title":"British National Formulary for Children","author":"National Insititute for Health and Care Excellence","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128503_bb0055","author":"UK Health Security Agency"},{"key":"10.1016\/j.vaccine.2026.128503_bb0060","series-title":"Summary of Product Characteristics: Bexsero suspension for injection in pre-filled syringe","author":"European Medicines Agency","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128503_bb0065","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128503_bb0070","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128503_bb0075","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128503_bb0080","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","article-title":"Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide","volume":"37","author":"Muzzi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128503_bb0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-1-4939-9202-7_15","article-title":"Flow cytometric assays to quantify fHbp expression and detect serotype specific capsular polysaccharides on Neisseria meningitidis","volume":"1969","author":"Loschko","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128503_bb0090","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02161-20","article-title":"Meningococcal deduced vaccine antigen reactivity (MenDeVAR) index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications","volume":"59","author":"Rodrigues","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2026.128503_bb0095","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"Brueggemann","year":"2021","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.vaccine.2026.128503_bb0100","first-page":"385","article-title":"Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England","volume":"87","author":"Clark","year":"2023","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.128503_bb0105","author":"Joint Committee on Vaccination and Immunisation (JCVI)"},{"key":"10.1016\/j.vaccine.2026.128503_bb0110","unstructured":"UK Health and Security Agency Recent increase in group B meningococcal disease among teenagers and young adults. https:\/\/www.gov.uk\/government\/news\/recent-increase-in-group-b-meningococcal-disease-among-teenagers-and-young-adults; 2022. [Accessed 3 September 2025]."},{"key":"10.1016\/j.vaccine.2026.128503_bb0115","series-title":"24th International Pathogenic Neisseria Conference (IPNC 2025); 2025 March 30\u2013April 4, 2025; Florence, Italy","article-title":"Ability of MenB-fHbp\u2013Containing Vaccines to Provide Immune Protection Against Serogroup B Sequence Type 1161 UK University Outbreak Strains","author":"Lucidarme","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128503_bb0120","article-title":"Professor Andrew Pollard on coronavirus vaccines","volume":"18","author":"Pollard","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128503_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00036-18","article-title":"Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine","volume":"9","author":"McNeil","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128503_bb0130","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.vaccine.2026.128503_bb0135","first-page":"385","article-title":"Added value of PCR-testing for confirmation of invasive meningococcal disease in England","volume":"67","author":"Heinsbroek","year":"2013","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.128503_bb0140","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","article-title":"Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the meningococcal reference unit","volume":"55","author":"Gray","year":"2006","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2026.128503_bb0145","doi-asserted-by":"crossref","first-page":"9990","DOI":"10.1038\/s41598-019-46483-3","article-title":"Outbreak strain characterisation and pharyngeal carriage detection following a protracted group B meningococcal outbreak in adolescents in South-West England","volume":"9","author":"Clark","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128503_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00172-5","article-title":"Invasive meningococcal disease and genome databases","volume":"2","author":"Karlsson","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128503_bb0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.12688\/wellcomeopenres.14826.1","article-title":"Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications","volume":"3","author":"Jolley","year":"2018","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2026.128503_bb0160","author":"PubMLST"},{"key":"10.1016\/j.vaccine.2026.128503_bb0165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128503_bb0170","unstructured":"Pfizer Inc. FDA Approves Penbraya\u2122, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-penbrayatm-first-and-only-vaccine-prevention; 2023. [Accessed 6 June 2025]."},{"key":"10.1016\/j.vaccine.2026.128503_bb0175","series-title":"European Society for Paediatric Infectious Diseases (ESPID)","article-title":"Phase 3, randomized, active-controlled trial demonstrates noninferiority of pentavalent meningococcal MenABCWY vaccine to MenB-fHbp + MenACWY-CRM, providing a high degree of protective immunity in healthy 10- to 25-year-olds","author":"Ostergaard","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128503_bb0180","author":"PubMLST"},{"key":"10.1016\/j.vaccine.2026.128503_bb0185","author":"PubMLST"},{"key":"10.1016\/j.vaccine.2026.128503_bb0190","author":"PubMLST"},{"key":"10.1016\/j.vaccine.2026.128503_bb0195","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal B vaccine in adolescents and young adults","volume":"347","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128503_bb0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.vaccine.2021.11.053","article-title":"A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults","volume":"40","author":"Drazan","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128503_bb0205","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128503_bb0210","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00261-17","article-title":"Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States","volume":"2","author":"Rajam","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2026.128503_bb0215","first-page":"136","article-title":"Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - first real-world data","volume":"84","author":"Lucidarme","year":"2022","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.128503_bb0220","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.vaccine.2017.01.066","article-title":"Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France","volume":"35","author":"Taha","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128503_bb0225","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00121-17","article-title":"Breadth and duration of meningococcal serum bactericidal activity in health care workers and microbiologists immunized with the MenB-FHbp vaccine","volume":"24","author":"Lujan","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128503_bb0230","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/INF.0000000000001399","article-title":"Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains","volume":"36","author":"Harris","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128503_bb0235","unstructured":"UK Health and Security Agency National enhanced surveillance of vaccination programmes targeting invasive meningococcal disease in England. https:\/\/assets.publishing.service.gov.uk\/media\/639b2e068fa8f5069707c0e3\/UKHSA-meningococcal-surveillance-december-2022.pdf; 2022. [Accessed 26 February 2026]."},{"key":"10.1016\/j.vaccine.2026.128503_bb0240","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2026.31.3.2500431","article-title":"First use of Trumenba (MenB-fHbp) vaccine to control a nursery outbreak of serogroup B invasive meningococcal disease involving children previously immunised with Bexsero (4CMenB), England, November 2023","volume":"31","author":"Foster","year":"2026","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128503_bb0245","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","article-title":"A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines","volume":"15","author":"Findlow","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128503_bb0250","author":"US Food and Drug Administration"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:01:04Z","timestamp":1792515664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"alternative-id":["S0264410X26003117"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128503","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ability of the MenB-fHbp vaccine to provide immune protection against meningococcal serogroup B ST-1161 UK university \u201cSouth West Outbreak\u201d strain isolates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128503"}}